

CBE ID

0632

Title

Primary Prevention of Cardiovascular Events in Diabetics – Use of Aspirin or Antiplatelet Therapy

Project

National Voluntary Consensus Standards For Clinically Enriched Administrative Data

Endorsement Status

Endorsement Removed

Is Under Review

No

Previous Endorsement Cycle

Full Year 2009

Removal Date

Mon, 02/03/2014 - 19:00

Initial Endorsement

Thu, 12/03/2009 - 19:00

Steward

ActiveHealth Management

1.0 New or Maintenance

Maintenance

1.1 Measure Structure

Single Measure

1.3 Electronic Clinical Quality Measure (eCQM)

No

1.6 Measure Description

The percentage of male diabetics, age 50 years or older, or female diabetics, aged 60 years or older, with a Framingham risk score > 10 who are taking aspirin or an antiplatelet agent.

1.7 Measure Type

Process

1.8 Level of Analysis

Clinician: Group/Practice, Clinician: Individual, Facility, Health Plan, Integrated Delivery System,

Other, Population: Community, County or City, Population: Regional and State

1.9 Care Setting

Home Care, Outpatient Services

1.14 Numerator

Patients with a refill for aspirin or antiplatelet therapy in the past 6 months

1.15 Denominator

Male diabetics, age 50 years or older, or female diabetics, aged 60 years or older, with a Framingham risk score > 10.

1.20 Types of Data Sources

Claims Data, Electronic Health Data, Electronic Health Records: Electronic Health Records, Instrument-Based Data, Other

6.1.2 Current or Planned Use(s)

Public Reporting, Quality Improvement (Internal to the specific organization)

6.1.3 Current Use(s)

Public Reporting, Quality Improvement (Internal to the specific organization)

Exclusions

Specific Exclusions:

1. Contraindications to aspirin therapy, including:

- Hemorrhage contraindications and procedures
- Neutropenia
- Thrombocytopenia
- Hematocrit lab value ≤ 25
- INR lab value > 1.6
- Platelet lab value ≤ 50
- WBC lab value < 2.0
- Chronic liver disease
- Aspirin intolerance
- Aspirin-induced asthma
- Intracerebral hemorrhage
- Coagulopathies (bleeding disorders)

2. Other denominator exclusions include:

- Warfarin use
- Long term anticoagulation therapy

General exclusions:

1. Evidence of metastatic disease or active treatment of malignancy (chemotherapy or radiation

- therapy) in the last 6 months;
2. Patients who have been in a skilled nursing facility in the last 3 months
 3. Patients who are terminally ill or in Hospice
 4. Patient or provider feedback indicating allergy, intolerance or other contraindication to Aspirin or Antiplatelet therapy anytime in the past

See attachment for code sets

Planned Use

Public Reporting, Quality Improvement (Internal to the specific organization)

Risk Adjustment

No risk adjustment or risk stratification

Steward Organization

ActiveHealth Management

Steward POC email

mvemireddy@activehealth.net